Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness

BACKGROUND: The serine protease inhibitor nafamostat has been proposed as a treatment for COVID-19, by inhibiting TMPRSS2-mediated viral cell entry. Nafamostat has been shown to have other, immunomodulatory effects, which may be beneficial for treatment, however animal models of ssRNA virus infectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yates, Abi G., Weglinski, Caroline M., Ying, Yuxin, Dunstan, Isobel K., Strekalova, Tatyana, Anthony, Daniel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734544/
https://www.ncbi.nlm.nih.gov/pubmed/34991643
http://dx.doi.org/10.1186/s12974-021-02357-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734544/
https://www.ncbi.nlm.nih.gov/pubmed/34991643
http://dx.doi.org/10.1186/s12974-021-02357-y

Ejemplares similares